Assessment of Regional Gastrointestinal Absorption of BMS-986165 Using Pharmacoscintigraphic Evaluation in Healthy Male Subjects
Latest Information Update: 04 Oct 2019
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Autoimmune disorders; Crohn's disease; Inflammatory bowel diseases; Liver disorders; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Systemic lupus erythematosus; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 27 Sep 2019 Status changed from recruiting to completed.
- 20 Mar 2019 New trial record